Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GTI-2040. Lorus Therapeutics.

R M Orr1

  • 1CRC Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK. rosanne@icr.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determining cut-off scores for simulated tasks in Brazilian Air Force military personnel.

BMJ military health·2024
Same author

Antisense therapy for cancer.

IDrugs : the investigational drugs journal·2008
Same author

Molecular targets and cancer therapeutics: discovery, development & clinical validation--AACR-NCI-EORTC international conference.

IDrugs : the investigational drugs journal·2005
Same author

Technology evaluation: leukemia therapy, University of Pennsylvania.

Current opinion in molecular therapeutics·2001
Same author

Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.

Current opinion in molecular therapeutics·2001
Same author

Patent review: therapeutic applications for antisense oligonucleotides 1999-2000.

Current opinion in molecular therapeutics·2001
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

GTI-2040, an antisense oligonucleotide targeting ribonucleotide reductase, shows promise in treating various cancers. Early trials indicate good tolerability and significant tumor growth inhibition, stabilization, and regressions across multiple tumor models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • GTI-2040 is an antisense oligonucleotide developed by Lorus Therapeutics.
  • It targets the R2 component of ribonucleotide reductase, an enzyme crucial for DNA synthesis and repair.
  • Ribonucleotide reductase is often overexpressed in cancer cells, making it a target for cancer therapy.

Purpose of the Study:

  • To evaluate the safety, tolerability, and preliminary efficacy of GTI-2040 in cancer patients.
  • To explore GTI-2040 as a monotherapy and in combination with other chemotherapeutic agents.
  • To assess the anti-tumor activity of GTI-2040 in various preclinical cancer models.

Main Methods:

  • Phase I/II clinical trials were initiated to assess GTI-2040 in cancer patients.

Related Experiment Videos

  • Preclinical studies involved testing GTI-2040 in nine different tumor models (colon, liver, lung, breast, kidney, ovary).
  • Combination therapy studies were planned with capecitabine for renal cell carcinoma.

    • Main Results:

    • GTI-2040 demonstrated significant inhibition of tumor growth, disease stabilization, and tumor regressions in preclinical models.
    • Phase I/II trials indicated that GTI-2040 was well tolerated with no apparent safety concerns.
    • The drug was evaluated as a monotherapy and in combination studies for renal cell carcinoma and planned for colorectal cancer.

    Conclusions:

    • GTI-2040 shows potential as an anticancer agent targeting ribonucleotide reductase.
    • The drug exhibits a favorable safety profile in early clinical trials.
    • Further investigation in phase II trials is warranted to confirm its efficacy in various cancer types.